Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia.
epidemiology
health-related quality of life
persistent symptoms
schizophrenia
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
06
2019
accepted:
09
10
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
8
1
2020
Statut:
epublish
Résumé
Generic health-related quality of life (HRQoL) scales are increasingly being used to assess the effects of new treatments in schizophrenia. The objective of this study is to better understand the usefulness of generic and condition specific HRQoL scales in schizophrenia by analyzing their correlates. Data formed part of the Pattern study, an international observational study among 1379 outpatients with schizophrenia. Patients were evaluated with the Mini International Neuropsychiatric Inventory, the Clinical Global Impression-Schizophrenia (CGI-SCH) Scale and the Positive and Negative Syndrome Scale (PANSS) and reported their HRQoL using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D). The two summary values of the SF-36 (the Mental Component Score and the Physical Component Score, SF-36 MCS and SF-36 PCS) were calculated. Higher PANSS positive dimension ratings were associated with worse HRQoL for the SQLS, EQ-5D VAS, SF-36 MCS, and SF-36 PCS. Higher PANSS negative dimension ratings were associated with worse HRQoL for the EQ-5D VAS, SF-36 MCS, and SF-36 PCS, but not for the SQLS or the EQ-5D tariff. PANSS depression ratings were associated with lower HRQoL in all the scales. There was a high correlation between the HRQoL scales. However, in patients with more severe cognitive/disorganized PANSS symptoms, the SQLS score was relatively higher than the EQ-5D tariff and SF-36 PCS scores. This study has shown substantial agreement between three HRQoL scales, being either generic or condition specific. This supports the use of generic HRQoL measures in schizophrenia. NCT01634542 (July 6, 2012, retrospectively registered).
Sections du résumé
BACKGROUND
BACKGROUND
Generic health-related quality of life (HRQoL) scales are increasingly being used to assess the effects of new treatments in schizophrenia. The objective of this study is to better understand the usefulness of generic and condition specific HRQoL scales in schizophrenia by analyzing their correlates.
METHODS
METHODS
Data formed part of the Pattern study, an international observational study among 1379 outpatients with schizophrenia. Patients were evaluated with the Mini International Neuropsychiatric Inventory, the Clinical Global Impression-Schizophrenia (CGI-SCH) Scale and the Positive and Negative Syndrome Scale (PANSS) and reported their HRQoL using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D). The two summary values of the SF-36 (the Mental Component Score and the Physical Component Score, SF-36 MCS and SF-36 PCS) were calculated.
RESULTS
RESULTS
Higher PANSS positive dimension ratings were associated with worse HRQoL for the SQLS, EQ-5D VAS, SF-36 MCS, and SF-36 PCS. Higher PANSS negative dimension ratings were associated with worse HRQoL for the EQ-5D VAS, SF-36 MCS, and SF-36 PCS, but not for the SQLS or the EQ-5D tariff. PANSS depression ratings were associated with lower HRQoL in all the scales. There was a high correlation between the HRQoL scales. However, in patients with more severe cognitive/disorganized PANSS symptoms, the SQLS score was relatively higher than the EQ-5D tariff and SF-36 PCS scores.
CONCLUSION
CONCLUSIONS
This study has shown substantial agreement between three HRQoL scales, being either generic or condition specific. This supports the use of generic HRQoL measures in schizophrenia.
CLINICALTRIALSGOV IDENTIFIER
BACKGROUND
NCT01634542 (July 6, 2012, retrospectively registered).
Identifiants
pubmed: 31908462
doi: 10.2147/NDT.S218578
pii: 218578
pmc: PMC6930014
doi:
Banques de données
ClinicalTrials.gov
['NCT01634542']
Types de publication
Journal Article
Langues
eng
Pagination
3475-3486Informations de copyright
© 2019 Domenech et al.
Déclaration de conflit d'intérêts
Carlo Altamura has served as a consultant or advisory board member for F. Hoffmann- La Roche, Ltd., Lundbeck, Merck, Astra Zeneca, Bristol Myers Squibb, Janssen-Cilag, Sanofi, Eli Lilly, Pfizer and Otsuka. Corrado Bernasconi is a contractor of F. Hoffmann- La Roche, Ltd. Helio Elkis has received research grants from the São Paulo Research Foundation (FAPESP), Janssen-Cilag and Roche, participated on advisory boards for Janssen-Cilag and Roche, and received honoraria and travel support from Janssen-Cilag and Roche. Ashok Malla has received honoraria or participated in advisory boards or educational conferences or received research funding for investigator-initiated projects from Janssen Canada, Pfizer Canada, Bristol-Myers-Squib, F. Hoffmann- La Roche, Ltd., Otsuka, Lundbeck and Astra-Zeneca. Francesco Margari has no conflict of interest. Anna-Lena Nordstroem is an employees of F. Hoffmann- La Roche, Ltd. Mathias Zink has received unrestricted scientific grants from the European Research Advisory Board, German Research Foundation, Servier, Pfizer Pharma GmbH, Bristol-Myers Squibb GmbH & CoKGaA, further speaker and travel support from Pfizer Pharma GmbH, Bristol-Myers Squibb, Otsuka, Astra Zeneca, Eli-Lilly, Janssen Cilag, Servier, Trommsdorff and F. Hoffmann- La Roche Ltd. Marie-Odile Krebs has received honoraria and participated in advisory boards F. Hoffmann- La Roche, Ltd. Josep Maria Haro has acted as a consultant, participated in advisory boards or given educational presentations for Eli Lilly and Co., Lundbeck, Otsuka, F. Hoffmann- La Roche Ltd. and Takeda. The authors report no other conflicts of interest in this work.
Références
Health Technol Assess. 2014 May;18(34):vii-viii, xiii-xxv, 1-188
pubmed: 24857402
Value Health. 2011 Sep-Oct;14(6):907-20
pubmed: 21914513
Psychiatry Res. 2019 Jan;271:39-45
pubmed: 30465980
Eur Psychiatry. 2005 Nov;20(7):510-9
pubmed: 16139488
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):239-44
pubmed: 15694230
Nord J Psychiatry. 2012 Feb;66(1):19-25
pubmed: 21770824
J Rheumatol. 2008 Aug;35(8):1528-37
pubmed: 18484697
Schizophr Res. 2016 Oct;176(2-3):387-391
pubmed: 27328889
Br J Psychiatry. 2009 Aug;195(2):170-7
pubmed: 19648552
Br J Psychiatry. 2005 Aug;187:121-30
pubmed: 16055822
Asian J Psychiatr. 2013 Oct;6(5):389-93
pubmed: 24011685
BMJ. 1993 May 29;306(6890):1437-40
pubmed: 8518639
Neuropsychiatr Dis Treat. 2017 Feb 23;13:567-576
pubmed: 28260904
Br J Psychiatry. 2006 Dec;189:508-14
pubmed: 17139034
Eur Psychiatry. 2005 Aug;20(5-6):403-8
pubmed: 16084068
Aging Ment Health. 2015 Jul;19(7):622-33
pubmed: 25209970
Schizophr Res. 2013 Dec;151(1-3):203-8
pubmed: 24183751
Schizophr Bull. 2007 Sep;33(5):1225-37
pubmed: 17204532
Int J Psychiatry Med. 2011;41(3):245-51
pubmed: 22073763
Aust N Z J Psychiatry. 2008 Jun;42(6):496-504
pubmed: 18465376
Schizophr Bull. 2012 Mar;38(2):304-15
pubmed: 20624752
Psychosom Med. 2002 May-Jun;64(3):510-9
pubmed: 12021425
Value Health. 2008 Dec;11(7):1162-9
pubmed: 18489492
Neuropsychiatr Dis Treat. 2019 Jan 21;15:293-301
pubmed: 30718955
Schizophr Res. 2001 Sep 1;51(2-3):171-80
pubmed: 11518637
Acta Psychiatr Scand Suppl. 2000;(407):33-7
pubmed: 11261637
Trials. 2013 Jul 17;14:222
pubmed: 23866815
Br J Psychiatry. 2000 Jul;177:42-6
pubmed: 10945087
Schizophr Res. 2015 Dec;169(1-3):234-240
pubmed: 26431792
Soc Psychiatry Psychiatr Epidemiol. 2009 May;44(5):361-8
pubmed: 18974910
BMJ. 2012 Feb 28;344:e846
pubmed: 22374932
Schizophr Res. 2008 Jan;98(1-3):201-8
pubmed: 17919890
Schizophr Res. 2016 Mar;171(1-3):27-34
pubmed: 26781001
Pharmacoeconomics. 2012 Mar;30(3):183-95
pubmed: 22263841
Psychiatry Res. 2019 Mar;273:387-393
pubmed: 30682561
Qual Life Res. 2015 Nov;24(11):2753-60
pubmed: 26038220
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):343-9
pubmed: 23763531
Schizophr Bull. 2006 Apr;32(2):214-9
pubmed: 16481659
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Qual Life Res. 1994 Feb;3(1):7-12
pubmed: 8142947
Qual Life Res. 1999 Aug;8(5):417-26
pubmed: 10474283
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Rheumatology (Oxford). 1999 Sep;38(9):807-13
pubmed: 10515639
Psychiatry Res. 2015 Aug 30;228(3):724-8
pubmed: 26077848
J Clin Psychiatry. 2009;70 Suppl 3:22-9
pubmed: 19570498
Health Econ. 1999 Feb;8(1):41-51
pubmed: 10082142
Br J Psychiatry. 2014 Sep;205(3):236-43
pubmed: 24855127
BMJ. 1997 Feb 22;314(7080):572
pubmed: 9055718
Qual Life Res. 2013 Dec;22(10):2909-20
pubmed: 23615959
Ann Acad Med Singapore. 2012 Oct;41(10):457-62
pubmed: 23138143
Qual Life Res. 1997 Jan;6(1):21-6
pubmed: 9062438
J Nerv Ment Dis. 2012 Jul;200(7):584-7
pubmed: 22759934
Med Care. 1999 Jul;37(7):678-91
pubmed: 10424639
Psychiatry Res. 2019 Sep;279:350-352
pubmed: 30902352
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
J Ment Health. 2017 Apr;26(2):119-126
pubmed: 27128492
Curr Med Res Opin. 2004 Jun;20(6):827-35
pubmed: 15200739
Psychol Bull. 1955 Jul;52(4):281-302
pubmed: 13245896
Psychopathology. 2005 Nov-Dec;38(6):320-6
pubmed: 16224206
Schizophr Res. 2003 Sep 1;63(1-2):137-49
pubmed: 12892868
Schizophr Res. 2014 Apr;154(1-3):83-8
pubmed: 24613000
Schizophr Res. 1995 Feb;14(3):229-34
pubmed: 7766534
Am J Geriatr Psychiatry. 2012 Dec;20(12):1016-25
pubmed: 23018474
Schizophr Res. 2003 Jul 1;62(1-2):73-6
pubmed: 12765746
Obes Rev. 2010 Sep;11(9):656-70
pubmed: 19780990
Acta Psychiatr Scand. 2016 Oct;134(4):360-7
pubmed: 27497263
Acta Psychiatr Scand. 2002 Apr;105(4):293-300
pubmed: 11942934
Am J Geriatr Psychiatry. 2017 Jul;25(7):755-765
pubmed: 28431868